Get started

Financials · AGL

agilon health inc. (AGL) financials

For the twelve months ended Sep 30, 2026, agilon health inc. reported $6.00B of revenue and -$87.10M of net income.

Revenue, TTM
$6.00B
Revenue growth, YoY
+2.0%
Net income, TTM
-$87.10M
Net margin
-1.5%
Free cash flow, TTM
-$17.01M
Cash
$174.40M
Total debt
$30.53M
P/S
0.32
Market cap
$1.90B
Annual revenue$5.93B
FY2019FY2025
Annual net income-$391.35M
FY2019FY2025
Annual free cash flow-$119.00M
FY2019FY2025

AGL revenue and earnings growth

AGL revenueQ3 2026$1.52B

Quarter YoY
+5.9%
QoQ
+1.7%
FY YoY
-2.1%
5Y CAGR
+37.2%

AGL revenue was $1.52B in fiscal Q3 2026 (ended Sep 30, 2026), up 5.9% from a year earlier and up 1.7% from the prior quarter. For the full fiscal 2025 it was $5.93B, down 2.1% from fiscal 2024. Compound annual growth was +37.2% over 5 years. It rose in 5 of the last 6 fiscal years.

AGL net incomeQ3 2026$34.91M

QoQ
+94.4%

AGL net income was $34.91M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$110.21M a year earlier and up 94.4% from the prior quarter. For the full fiscal 2025 it was -$391.35M, compared with -$260.15M in fiscal 2024.

AGL EPSQ3 2026$1.97

QoQ
+89.4%

AGL diluted EPS was $1.97 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$6.65 a year earlier and up 89.4% from the prior quarter. For the full fiscal 2025 it was -$0.98, compared with -$0.61 in fiscal 2024.

AGL free cash flowQ3 2026$46.62M

AGL free cash flow was $46.62M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$21.33M a year earlier. For the full fiscal 2025 it was -$119.00M, compared with -$71.03M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue$5.93B$6.06B$4.32B$2.39B$1.52B$1.22B$794.41M
Selling, general and admin$238.54M$268.91M$285.76M$207.79M$427.50M$137.29M$122.83M
Operating income-$463.24M-$292.13M-$232.13M-$105.38M-$372.24M-$56.67M-$106.57M
Interest expense$6.64M$6.18M$6.66M$4.48M$6.15M$8.13M$9.07M
Pre-tax income-$404.10M-$248.83M-$194.46M-$90.67M-$382.98M-$62.34M-$114.69M
Income tax$1.25M$1.45M$791.0K$1.64M$886.0K$865.0K-$232.0K
Net income-$391.35M-$260.15M-$262.60M-$106.55M-$406.49M-$60.05M-$282.59M
EPS, basic-$0.98-$0.61-$0.48-$0.22-$1.03-$0.20-
EPS, diluted-$0.98-$0.61-$0.48-$0.22-$1.03-$0.20-
Diluted shares414.0M411.0M408.9M408.2M372.9M323.5M294.7M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Cash and equivalents$173.71M$188.23M$114.33M$475.91M$1.05B$128.20M$139.15M
Short-term investments---$411.90M$0--
Receivables$673.79M$1.02B$942.46M$492.36M$293.41M$144.56M-
Current assets$1.10B$1.46B$1.48B$1.45B$1.37B$294.20M-
Goodwill$0$24.13M$24.13M$2.51M$41.54M$41.54M-
Total assets$1.27B$1.73B$1.74B$1.70B$1.59B$446.36M-
Current liabilities$1.08B$1.15B$977.16M$535.09M$356.96M$266.83M-
Short-term debt$19.24M$0$6.25M$5.00M$5.00M$3.04M-
Long-term debt$15.75M$34.90M$32.31M$38.48M$43.40M$64.67M-
Total debt$34.99M$34.90M$38.56M$43.48M$48.40M$67.71M-
Total liabilities$1.14B$1.26B$1.08B$656.86M$494.66M$421.59M-
Shareholders' equity$126.73M$470.95M$661.02M$1.04B$1.09B-$284.73M-$232.03M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Operating cash flow-$105.76M-$57.78M-$156.20M-$130.81M-$148.16M-$53.20M-$103.86M
Capital expenditures$13.24M$13.25M$15.83M$15.43M$6.56M$1.77M$2.89M
Free cash flow-$119.00M-$71.03M-$172.03M-$146.23M-$154.72M-$54.98M-$106.75M
Investing cash flow$88.61M$139.89M-$44.02M-$444.39M-$90.51M$22.07M-$5.06M
Financing cash flow-$2.99M-$2.58M-$193.13M$28.06M$1.15B$24.62M$176.30M
Share repurchases--$200.00M--$6.70M-
Stock-based compensation$49.12M$50.66M$69.50M$28.38M$292.39M$6.69M$5.22M
Depreciation and amortization$28.59M$24.46M$20.16M$13.77M$14.67M$14.10M$41.41M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue growth, YoY-2.1%40.4%80.7%57.0%24.9%53.4%-
Operating margin-7.8%-4.8%-5.4%-4.4%-24.5%-4.7%-13.4%
Net margin-6.6%-4.3%-6.1%-4.5%-26.7%-4.9%-35.6%
Free cash flow margin-2.0%-1.2%-4.0%-6.1%-10.2%-4.5%-13.4%
Return on equity-308.8%-55.2%-39.7%-10.2%-37.2%--
Return on assets-30.8%-15.0%-15.1%-6.3%-25.6%-13.5%-
Current ratio1.021.271.512.713.831.10-
Debt to equity0.280.070.060.040.04--

Source: XBRL data agilon health inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

AGL peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
AGL$6.00B+2.0%-$87.10M-1.5%$1.90B
FMS€19.63B+1.5%€978.37M5.0%$13.07B
DVA$14.17B+6.4%$920.08M6.5%$12.04B
SHC$1.23B+6.9%$173.47M14.1%$4.57B
PGNY$1.34B+5.5%$91.02M6.8%$2.67B
VMD$310.37M+21.8%$15.89M5.1%$346.0M
CCEL$31.13M-2.0%-$1.95M-6.2%$39.4M
NIVF$23.71M+336.3%$9.88M41.7%$4.5M

AGL FAQ

7 questions
  • What is AGL revenue?
    agilon health inc. (AGL) reported $6.00B of revenue for the twelve months ended Sep 30, 2026. That is up 2.0% from the year before. Revenue for fiscal 2025 was $5.93B.
  • Is AGL profitable?
    No. agilon health inc. reported a net loss of $87.10M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does AGL have?
    agilon health inc. reported $174.40M in cash and cash equivalents and $30.53M of debt on its most recent balance sheet in SEC filings.
  • How fast is AGL revenue growing?
    agilon health inc.'s revenue changed -2.1% in fiscal 2025, to $5.93B. Its compound annual growth rate was +37.2% over 5 years.
  • What is AGL free cash flow?
    agilon health inc. generated -$17.01M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$4.23M less capital expenditures.
  • When did AGL last report financial results?
    The latest statements here come from agilon health inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.
  • Where does this AGL financial data come from?
    Quantisnow builds these statements from the structured XBRL data agilon health inc. files with the SEC. It is provided for information only and is not investment advice.